Copyright
©The Author(s) 2018.
World J Gastroenterol. Feb 28, 2018; 24(8): 917-928
Published online Feb 28, 2018. doi: 10.3748/wjg.v24.i8.917
Published online Feb 28, 2018. doi: 10.3748/wjg.v24.i8.917
Variable | Overall HBV patients (n = 3358) | Propensity score-matched HBV patients (n = 1768) | ||||||
Crude | Adjusted1 | Crude | Adjusted1 | |||||
HR (95%CI) | P value | HR (95%CI) | P value | HR (95%CI) | P value | HR (95%CI) | P value | |
HBV cohort | ||||||||
Untreated | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) | ||||
Treated | 0.17 (0.07-0.41) | < 0.0001 | 0.15 (0.06-0.36) | < 0.0001 | 0.14 (0.06-0.34) | < 0.0001 | 0.13 (0.05-0.31) | < 0.0001 |
Sex (Men/Women) | 1.12 (0.84-1.49) | 0.43 | 0.91 (0.46-1.79) | 0.78 | 0.87 (0.58-1.30) | 0.49 | 0.63 (0.24-1.63) | 0.34 |
Age (per year) | 1.02 (1.01-1.02) | 0.0002 | 1.00 (0.98-1.02) | 0.86 | 1.01 (1.00-1.02) | 0.20 | 0.99 (0.96-1.01) | 0.34 |
Comorbidity (Yes/No) | ||||||||
Diabetes | 2.01 (1.52-2.67) | < 0.0001 | 1.92 (1.33-2.77) | 0.0005 | 1.89 (1.31-2.74) | 0.0007 | 1.77 (1.08-2.91) | 0.024 |
Hypertension | 3.09 (2.35-4.06) | < 0.0001 | 3.90 (2.66-5.72) | < 0.0001 | 2.59 (1.79-3.74) | < 0.0001 | 3.52 (2.09-5.95) | < 0.0001 |
Coronary heart disease | 0.85 (0.53-1.36) | 0.49 | 0.51 (0.31-0.84) | 0.008 | 0.93 (0.54-1.60) | 0.80 | 0.59 (0.32-1.09) | 0.09 |
Hyperlipidemia | 1.12 (0.81-1.54) | 0.51 | 0.84 (0.58-1.20) | 0.33 | 1.23 (0.81-1.86) | 0.33 | 0.98 (0.61-1.56) | 0.91 |
Cirrhosis | 0.57 (0.27-1.22) | 0.15 | 0.35 (0.05-2.61) | 0.30 | 0.53 (0.25-1.14) | 0.10 | 0.30 (0.03-3.32) | 0.33 |
Urbanization level | ||||||||
Urban | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) | ||||
Suburban | 1.18 (0.90-1.56) | 0.24 | 1.18 (0.85-1.65) | 0.33 | 1.27 (0.88-1.84) | 0.20 | 1.06 (0.68-1.64) | 0.80 |
Rural | 1.03 (0.75-1.43) | 0.85 | 1.09 (0.73-1.64) | 0.68 | 0.79 (0.50-1.23) | 0.30 | 0.91 (0.52-1.59) | 0.73 |
Enrolee category | ||||||||
1 + 2 | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) | ||||
3 | 0.96 (0.73-1.27) | 0.78 | 1.05 (0.74-1.50) | 0.78 | 0.79 (0.54-1.14) | 0.21 | 0.99 (0.60-1.62) | 0.97 |
4 | 1.57 (1.14-2.16) | 0.006 | 1.60 (1.06-2.40) | 0.024 | 1.78 (1.19-2.67) | 0.005 | 1.89 (1.10-3.26) | 0.022 |
- Citation: Chen YC, Li CY, Tsai SJ, Chen YC. Nationwide cohort study suggests that nucleos(t)ide analogue therapy decreases dialysis risk in Taiwanese chronic kidney disease patients acquiring hepatitis B virus infection. World J Gastroenterol 2018; 24(8): 917-928
- URL: https://www.wjgnet.com/1007-9327/full/v24/i8/917.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i8.917